Biogen, Eisai’s lecanemab will get Alzheimer’s nod, however how profitable it will likely be is unsure


Old man patient

agrobacter/iStock through Getty Photos

The US FDA on Friday granted accelerated approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALY) Leqembi (lecanemab), simply the second biologic medication ever permitted for Alzheimer’s illness.

The remedy is anticipated to grow to be obtainable across the

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles